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A B S T R A C T
Introduction: Aromatase-inhibitors (AIs) are commonly used for treatment of
patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care
screening tool for fracture risk is bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA). The fracture risk assessment tool (FRAX®) may be used in
conjunction with BMD to identify additional osteopenic patients at risk of fracture who may beneﬁt from a bone-modifying agent (BMA). The trabecular bone score
(TBS), a novel method of measuring bone microarchitecture by DXA, has been shown to be an independent indicator of increased fracture risk. We report how the
addition of TBS and FRAX®, respectively, to BMD contribute to identiﬁcation of elevated fracture risk (EFR) in postmenopausal breast cancer patients treated with
AIs.
Methods: 100 patients with early stage hormone-positive breast cancer treated with AIs, no prior BMAs, and with serial DXAs were identiﬁed. BMD and TBS were
measured from DXA images before and following initiation of AIs, and FRAX® scores were calculated from review of clinical records. EFR was deﬁned as either: BMD
≤−2.5 or BMD between −2.5 and −1 plus either increased risk by FRAX® or degraded microstructure by TBS.
Results: At baseline, BMD alone identiﬁed 4% of patients with EFR. The addition of FRAX® increased detection to 13%, whereas the combination of BMD, FRAX® and
TBS identiﬁed 20% of patients with EFR. Following AIs, changes in TBS were independent of changes in BMD. On follow-up DXA, BMD alone detected an additional 1
patient at EFR (1%), whereas BMD+ FRAX® identiﬁed 3 additional patients (3%), and BMD+FRAX®+TBS identiﬁed 7 additional patients (7%).
Conclusions: The combination of FRAX®, TBS, and BMD maximized the identiﬁcation of patients with EFR. TBS is a novel assessment that enhances the detection of
patients who may beneﬁt from BMAs.
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1. Introduction
Aromatase-Inhibitors (AIs) are commonly used in the treatment of
post-menopausal women with a history of hormone receptor-positive
breast carcinoma, and have been shown to decrease bone mineral
density (BMD) and increase the risk of bone fragility fractures [1].
The National Comprehensive Cancer Network Task Force (NCCN)
currently recommends screening of fracture risk in all patients initiating
AIs by obtaining clinical history, dual-energy X-ray absorptiometry
(DXA) scans and with the use of the fracture risk assessment tool
(FRAX®) calculator. If T-score is less than or equal to−2.0 at any site or
if the FRAX® 10-year absolute risk of fracture is greater than 20% for
any major fracture or greater than 3% for hip fracture, bone modifying-
agents (BMAs) such as bisphosphonates or denosumab, are re-
commended. For women with increased risk of fractures initiating AI
therapy, BMAs such as bisphosphonates or denosumab can be re-
commended, both which have been shown to decrease the risk of bone
fracture in the setting of AI therapy [2,3]. The current gold standard
screening tool for the diagnosis of osteoporosis in the absence of fra-
gility fractures is DXA.
Many patients without osteoporotic BMD suﬀer fragility fractures. It
is important to highlight that the majority of fractures actually occur in
patients with a T-score above the osteoporotic range [4], making the
osteoporosis threshold (BMD T score < 2.5) inadequate to identify all
patients at risk. Furthermore, BMD does not evaluate the degree of bone
microarchitectural deterioration, which may represents an independent
factor contributing to increased bone fragility [5].
The trabecular bone score (TBS) is an innovative gray-level texture
measurement that utilizes lumbar spine DXA images to discriminate
changes in bone microarchitecture [6]. Speciﬁcally, TBS measures tri-
dimensional bone areas with diﬀerent trabecular and microstructural
characteristics. TBS has been shown to be an independent indicator of
increased fracture risk [7]. Furthermore, the combination of TBS mi-
crostructure evaluation with BMD measured by DXA has been shown to
be superior to either measurement alone in the assessment of fracture
risk [8].
In an eﬀort to optimize the identiﬁcation of postmenopausal women
treated with adjuvant AIs at risk of bone fragility fractures, we eval-
uated a screening model that integrates the novel TBS tool with FRAX®
and DXA. We then studied if our tools represent independent variables
in this clinical context, and enumerated the relative contribution of
adding TBS to the standard screening approaches most commonly ob-
served in the clinic (BMD±FRAX®).
2. Materials and methods
2.1. Patient selection
Patients were identiﬁed via institutional databases at Memorial
Sloan Kettering Cancer Center under an Institutional Review Board
waiver of consent. Using DataLine services we identiﬁed 309 unique
patients who were diagnosed with breast cancer at MSKCC between the
years of 2005 and 2012, who were post-menopausal (deﬁned as ≥60
years old or ≥50 years old with amenorrhea for> 12 months), were
treated with an AI, and who had at least 2 DXAs performed at MSKCC.
Through a chart review, we then eliminated patients who were treated
with BMAs prior to baseline or follow-up DXA. We also excluded all
patients with a BMI over 37, as TBS has not been validated in this
population. We then selected the patients who had a baseline DXA
within 3 months of starting the AI, and a follow up DXA more than 6
months but less than 36 months after the ﬁrst one. This search yielded
to 100 unique patients who were included in our analysis.
2.2. BMD, TBS, and FRAX assessment
As per standard-of-care at MSKCC, BMD from femoral neck, total
hip and lumbar spine was measured by DXA (GE-lunar). TBS mea-
surements were performed in the Bone Disease Center at the Lausanne
University Hospital (CHUV), Lausanne, Switzerland (TBS iNsight®
Software version 1.8, Med-Imaps, Pessac, France) using anonymized
spine DXA ﬁles to ensure blinding of the Swiss investigators to all
clinical parameters and outcomes. The approach was similar to the one
used in other studies [7]. BMD and TBS were evaluated at baseline and
at follow-up. FRAX® score was calculated utilizing the clinical in-
formation from patients’ charts, and using the online algorithm [9].
BMD was interpreted using World Health Organization (WHO)
guidelines, which deﬁne risk according to T-score, which is the stan-
dard deviation diﬀerence between a patient's BMD and that of a young-
adult reference population. A T-score of ≤−2.5 indicates clinical os-
teoporosis. Osteopenia is deﬁned as a borderline T-score (between
−1.0 and −2.5), whereas normal BMD is deﬁned as T-score>−1.0.
TBS, being a continuous variable as BMD, was interpreted using the
tertile approach extracted from the fracture data of a large Canadian
cohort. Degraded microarchitecture represents the highest risk, and is
deﬁned as a TBS value of ≤1.2. Partially degraded microarchitecture
represents borderline risk, and is deﬁned as values between 1.2 and
1.35, whereas normal microarchitecture is deﬁned as TBS≥1.35 [6,7].
FRAX® assessment was conducted via retrospective medical records
review and calculated through the online algorithm (https://www.shef.
ac.uk/FRAX).
2.3. Deﬁnition of at-risk populations
Using BMD, TBS, and FRAX®, we evaluated three screening para-
digms for identifying patients with high fracture risk who would be
suitable for pharmacologic therapy with a BMA. The ﬁrst screening
paradigm is BMD alone using osteoporosis (T≤−2.5) as a threshold for
positivity. The National Osteoporosis Foundation recommends BMA
therapy for this population based upon models that predict a favorable
cost-beneﬁt ratio [10].
The second screening paradigm is BMD plus FRAX®, which is the
standard screening practice endorsed by the National Comprehensive
Cancer Network (NCCN) and National Osteoporosis Foundation [10].
For BMD plus FRAX®, the threshold for positivity is either osteoporosis
by BMD, or osteopenia by BMD plus a FRAX 10-year probability of a hip
fracture ≥3% or a 10-year probability of a major osteoporosis-related
fracture ≥20%. These thresholds were determined based upon mod-
eling predicting favorable cost-beneﬁt ratio, speciﬁc to the United
States population [10].
Finally, we tested a novel screening paradigm of BMD plus FRAX®
plus TBS. For this method, we deﬁned positivity to elevated fracture
risk (EFR) as either: 1) osteoporosis by BMD (T-score ≤−2.5); 2) os-
teopenia + high FRAX® score (as above); or 3) osteopenia + low TBS
score (degraded microarchitecture, i.e. TBS ≤1.2).
2.4. Statistical analysis
Statistical analysis was performed using IBM Statistical Package for
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the Social Sciences (SPSS)®. 0.05 was set as a threshold for statistical
signiﬁcance. Kolmogorov-Smirnov test ascertained normal distribution
of data. Pearson's correlation was calculated to assess the association
between TBS and BMD, one-way repeated measure ANOVA (using
Mauchly's test to assess assumption of sphericity) and simple linear
regression to assess prediction of TBS total percentage change by TBS at
baseline, BMI, race, age at beginning of treatment, DXA interval and
type of AI. All comparisons were two-tailed.
3. Results
3.1. Subject characteristics
Baseline demographic and clinical characteristics, as well as TBS
and lumbar spine (LS) BMD values, are summarized in Table 1. Median
age was 67 years (range 51–87 years) and median BMI was 27.5 kg/m2
(range 18.8–36.6 kg/m2). The majority of patients were treated with a
non-steroidal AI (95%: 70, anastrozole; 24, letrozole; 1, letrozole fol-
lowed by anastrozole), whereas 5% of patients were treated with a
steroidal AI (5, exemestane).
At baseline, 45 subjects had normal BMD (45%), 51 subjects met
WHO criteria for osteopenia (51%), and 4 subjects met criteria for os-
teoporosis (4%). By TBS, 33 subjects had normal bone micro-
architecture (33%), whereas 47 subjects had partially degraded mi-
croarchitecture (47%) and 20 subjects had degraded microarchitecture
(20%).
3.2. Analysis of combined screening approach of BMD+FRAX+TBS at
baseline
We assessed the ability of the three screening approaches (BMD
alone, BMD + FRAX®, or combined BMD + FRAX® + TBS) to identify
post-menopausal breast cancer patients at risk of fragility fracture. At
baseline DXA, only 4% of patients (n=4/100) met criteria for EFR by
BMD alone corresponding to a number needed to screen
(NNS=#screened /#diagnosed) of 25. With the addition of the FRAX®
assessment tool, 13% of patients (n=13/100) met criteria for EFR,
corresponding to a NNS of 8. Finally, with the combined approach in-
cluding TBS, 20% of patients (n=20/100) met criteria for EFR,
corresponding to a NNS of 5. Fig. 2a illustrates the breakdown of how
subjects are classiﬁed according to each of the screening approaches.
3.3. Analysis of combined screening approach of BMD+FRAX®+TBS
during AI therapy
We then evaluated the ability of each of the screening approaches to
detect AI-associated fracture risk among patients who did not have EFR
at baseline. In this data series, follow-up DXA was performed on
average 21 months following initiation of AI (12–35 months). Eighty
subjects did not exhibit EFR at baseline. At follow-up, one additional
subject developed EFR by BMD criteria, versus an additional 3 subjects
by BMD + FRAX® criteria, versus an additional 7 subjects by BMD +
FRAX®+TBS criteria. Despite less profound percentage changes in TBS
on average across all patients, changes in TBS were more likely to in-
ﬂuence the determination of EFR following initiation of AI. Fig. 2b il-
lustrates the breakdown according to each of the screening approaches.
In summation, a BMD-only screening approach with baseline and
follow-up DXA exhibited a NNS of 20, versus NNS of 6 for BMD plus
FRAX®, versus NNS of 4 for BMD plus FRAX ®plus TBS.
3.4. Eﬀect of AI on TBS and BMD
AI therapy was associated with statistically signiﬁcant declines in
lumbar spine BMD (mean annual decline: −0.45 T-score units, or
−1.5%; p<0.001) but not in TBS (mean annual decline:−0.15 units,
or −0.5%, NS).
Neither age, ethnicity, BMI, nor AI type appeared to inﬂuence
baseline BMD, TBS, or changes in BMD or TBS following AI (Table 1).
However, the TBS score at baseline inﬂuenced the likelihood of TBS
declines associated with AI therapy: subjects with low TBS scores at
baseline (as deﬁned by degraded microarchitecture, i.e. TBS ≤1.2)
were less likely to experience further declines in TBS, whereas subjects
with normal TBS at baseline were more likely to experience declines in
TBS. This ﬁnding reached statistical signiﬁcance (p<0.1), with mean
percentage declines of normal TBS group being −3.7%, versus −0.9%
in the partially degraded microarchitecture group and +3.9% in the
degraded microarchitecture group. Conversely, declines in BMD did not
appear to be inﬂuenced by baseline BMD.
Table 1
Trends in BMD and TBS, organized by clinical and demographic characteristics.
Group LS BMD, Baseline TBS, Baseline TH BMD, baseline ΔLS BMD/yr ΔTBS/yr
All Patients −0.04 1.29 −0.39 −0.45 (−1.5%) −0.15 (−0.5%)
Age
≤65 y (n=39) −0.08 1.32 −0.17 −0.12 (−1.2%) −0.01 (−0.8%)
>65 (n=61) −0.01 1.27 −0.52 −0.14 (−1.7%) −0.01 (−0.3%)
BMI
BMI≤25 (n=30) −0.51 1.3 −0.73 −0.16 (−1.3%) −0.01 (−0.6%)
BMI> 25 (n=70) 0.16* 1.28 −0.24 −0.12 (−1.5%) −0.01 (−0.4%)
Ethnicity
Caucasian (n=51) −0.23 1.32 −0.7 −0.15 (−2.3%) −0.01 (−0.9%)
Other (n=49) 0–17 1.26 −0.05 −0.12 (−1.9%) 0.00 (0%)
AI type
Anastrozole (n=70) −0.06 1.29 −0.44 −0.12 (−1.3%) −0.01 (−0.8%)
Exemestane (n=5) −0.24 1.32 0.22 −0.24 (−2.8%) −0.02 (−1.4%)
Letrozole (n=24) 0.34 1.27 −0.39 −0.17 (−1.7%) 0.01 (0.9%)
Baseline LS BMD
T≤−1.0 (n=35) −1.71 1.26 −1.03 −0.09 (1.8%) −0.01 (−0.2%)
T>−1.0 (=65) 0.86* 1.3 −0.05 −0.16 (1.3%) −0.01 (−0.6%)
Baseline TBS
TBS≤1.35 (n=68) −0.24 1.22 −0.49 −0.14 (−1.3%) 0.02 (0.4%)
TBS>1.35 (n=32) 0.39 1.43* −0.18 −0.11 (−1.8%) 0.03 (−2.2%)*
Legend: LS, lumbar spine; BMD, bone mineral density; TBS, trabecular bone score; Δ, change; y, year; AI, aromatase inhibitor.
* p<0.05/
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3.5. BMD and TBS are diﬀerentially inﬂuenced by AI therapy
We then evaluated whether BMD and TBS were independent vari-
ables in this dataset. Fig. 1 illustrates the correlation between TBS va-
lues and lumbar spine BMD, with each data point representing an in-
dividual DXA scan. We observed a weak positive relationship between
BMD and TBS (Pearson r=0.19, p=0.007), indicating that subjects
with preserved BMD may be more likely to have non-degraded bone
microarchitecture. We next evaluated for correlations in changes in
BMD versus TBS following initiation of AI. To control for variations in
the time interval between serial DXA scans, we plotted the annual
percentage change in BMD versus the annual percentage change in TBS.
With this approach, we found no correlation in change in BMD versus
change in TBS (Pearson r=0.07, NS), suggesting that AI may diﬀer-
entially inﬂuence BMD versus TBS within individual patients. Fur-
thermore, no correlations were identiﬁed when repeated for absolute
annual change (i.e. change in BMD/yr versus change in TBS/yr), or
non-adjusted changes (i.e. change in BMD versus change in TBS, or %
change in BMD versus % change in TBS) (data not shown).
3.6. The majority of cases of EFR are detected when follow-up DXAs are
performed greater than 18 months following initiation of AI
Substantial heterogeneity exists in clinical practice with regards to
the timing of repeat DXA following the initiation of AI. In our dataset,
we wished to ascertain and compare the rate of detection of acquired
EFR with an early detection strategy (i.e. DXA within 18 months of AI
initiation) versus a delayed detection strategy (i.e. DXA>18 months
following AI initiation). Excluding patients who had high fracture risk
at baseline, 30% of subjects (n=24/80) were evaluated with an “early”
DXA (interval range 11–18 months, average 13.8, SD 2.2), whereas
70% of subjects (n=56/80) were evaluated with a “delayed” DXA
(interval range 18–35 months, average 24.5, SD 3.2). In the early DXA
group, only one subject (4%) developed EFR following AI (as identiﬁed
by a decrease in TBS). Contrastingly, the majority of EFR was detected
in the delayed DXA group, with 6 patients detected (11%) ( Fig. 3).
These data correspond with a NNS of 24 associated with early DXA
scans, versus 13 for delayed DXA scans.
4. Discussion
Patients treated with AIs are at increased risk of fragility fractures,
and BMD assessment alone is unable to identify all patients at risk.
Recently, numerous alternative risk-assessment tools have been devel-
oped to better estimate fracture risk, which may allow for a more ef-
ﬁcient preventative approach in patients receiving AI.
The most extensively validated tool is the FRAX®, a computer-based
algorithm that calculates risk of fracture based on BMD and clinical
factors [11]. In the setting of AI therapy, FRAX® facilitates the decision
of whether to administer BMAs in women with borderline BMD (os-
teopenia). A major advantage of FRAX® is that it utilizes readily-
available clinical information. FRAX®, however does not speciﬁcally
assess the risk of fracture in women with breast cancer treated with AIs
and may underestimate their eﬀects on bone [12].
Furthermore, methodologies that assess bone quality and predict
fracture risk have emerged. A large body of evidence validates the
utility of TBS in predicting fragility fracture [13,14]. In the largest
longitudinal series, the Manitoba study, TBS and BMD were evaluated
in 29,407 women (> 50 years of age) and followed for fragility frac-
tures. With a median follow up of 4.7 years, TBS emerged as a highly
signiﬁcant predictor of fracture. Women with osteopenia and low TBS
values exhibited fracture rates on par with that of women with osteo-
porosis, suggesting that TBS may also help facilitate the decision to
treat with a BMA [7]. Such ﬁndings were corroborated in an interna-
tional meta-analysis of 14 studies (excluding the Manitoba cohort) —
together incorporating 17,809 men and women (59% women) ranging
in age from 40 to 90 years (mean age 72). The gradient of risk per
standard deviation decrease of TBS for hip fracture or other major os-
teoporotic fracture (clinical spine, distal forearm or proximal humerus
fracture) ranged from 1.31 to 1.54 depending on age and fracture
outcome with no diﬀerence between men and women. Such level of risk
Fig. 1. Correlations of BMD with TBS. A: Correlation of intra-patient BMD (lumbar spine) versus TBS at baseline; B: Correlation of changes in BMD versus TBS over time, calculated as
annual rate of change. Legend: BMD, bone mineral density; TBS, trabecular bone score.
Fig. 2. Detection of EFR using various screening strategies. A: Distribution of EFR pa-
tients detected on baseline DXA, by BMD alone, BMD+FRAX®, or BMD+FRAX®+TBS; B:
Distribution of EFR detected on follow-up DXA. Legend: DXA, dual-energy X-ray absor-
bimetry; BMD, bone mineral density; FRAX®, fracture risk assessment tool; TBS, trabe-
cular bone score. Gray boxes indicate designation of EFR.
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remained signiﬁcant even after adjustment for both spine BMD and
clinical risk factors [8].
We conducted a retrospective analysis to compare a BMD-alone
strategy, versus BMD+FRAX® and BMD+FRAX®+TBS screening stra-
tegies. To our knowledge, this constitutes the ﬁrst study to assess the
relative contributions of FRAX® and TBS. In our cohort, FRAX®+BMD
identiﬁed 9 (9%) additional patients at increased risk for fractures at
baseline and 2 (2%) after AI treatment compared to BMD alone, thus
corroborating the current National Comprehensive Cancer Network and
National Osteoporosis Foundation guidelines to conduct FRAX® as-
sessment in osteopenic women who require AI [10]. Likewise, the ad-
dition of TBS increased the numbers of at-risk patients detected both at
baseline (an additional 16, 16%) and at follow-up (an additional 6, 6%)
compared to BMD alone.
Consistent with other reports [15,16], the eﬀect of AI on TBS did not
appear to correlate with changes in BMD, suggesting that these two risk
assessments may be complementary rather than overlapping, and could
potentially be combined to create a more sensitive measure of bone
fragility. Our conclusions are corroborated by two small previous stu-
dies evaluating the inﬂuence of AI on TBS. In one study, 34 breast
cancer patients treated with AI were evaluated with both BMD and TBS,
and sustained a decrease of 5.9% and 2.1%, respectively, across a mean
DXA interval of 2.1 years (corresponding to a rate of loss of 2.8% and
1% annually) [15]. Another study evaluated the eﬀect of exemestane on
TBS in 19 patients, and showed a TBS decrease of 2.3% at 24 months
(corresponding to a mean annual decrease of 1.2%) [16]. These ﬁnd-
ings are generally consistent with our study, which demonstrated mean
annual decreases of 1.5% for BMD and 0.5% for TBS.
One unique ﬁnding from our dataset is that subjects with normal
TBS at baseline are more likely to experience declines in TBS, whereas
subjects with low TBS at baseline do not experience further declines.
We speculate that this ﬁnding may reﬂect variations in sensitivity of the
measurement assay across high versus low TBS ranges, and indicate
that the TBS measurement platform may have highest sensitivity for
detecting changes in the normal range. This ﬁnding, combined with the
ﬁnding that TBS contributed the most to identifying patients’ AI-asso-
ciated fracture risk, supports a practice of obtaining serial TBS mea-
surements in patients with normal TBS at baseline, but may argue that
serial measurement in patients with low TBS is less informative, as this
population might already be at high risk of fracture.
In our study, the decline in TBS during AIs treatment was not sta-
tistically signiﬁcant. Changes in TBS after osteoporosis therapy are
known to be of lesser magnitude than corresponding changes in BMD;
conversely, it is possible that BMD losses in the setting of AI therapy
occur in similar fashion [13]. Additionally, longer follow up might have
demonstrated the decline in TBS associated with relatively longer use of
AIs (mean 2.1 years) that others have demonstrated [15]. Furthermore,
patients in our study with follow up DXA after> 18 months of AI
treatment were more likely to experience EFR than< 18 months of
follow up. Thus, serial TBS measurements appear to identify subjects
with newly-acquired fracture risk following initiation of AI therapy
with greater sensitivity following 18 months on AI. Future studies as-
sessing TBS after longer follow up are needed to further evaluate AI-
associated changes in trabecular microstructure over ﬁve to ten years.
In summary, our analysis supports further evaluation of a screening
approach of BMD+FRAX®+TBS, obtained at baseline and at 2 years
following AI, with special attention paid to patients with osteopenia
and non-degraded bone microarchitecture by TBS. An alternative ap-
proach could be the use of TBS-adjusted FRAX BMD as it has been re-
cently proposed [8]. This later approach would still have to be tested in
this very speciﬁc population.
Recently published European consensus guidelines suggest that the
use of bisphosphonates should be considered for the prevention of
cancer treatment-induced bone loss in all patients with a T-score
of<−2.0 [17]. According to this approach, 7 additional patients
would have been identiﬁed at baseline in our population based on DXA
alone, of these 2 would have been identiﬁed by the combined approach
of osteopenia + low TBS score, 2 by osteopenia + high FRAX® score,
and 1 by both osteopenia + low TBS score and osteopenia + high
FRAX®. Only 28% of patients identiﬁed by the combined approach
osteopenia + low TBS score would have been identiﬁed by lowering
the T-score threshold. This result suggests that modiﬁcation of T-score
threshold would not hamper the usefulness of TBS.
Our ﬁndings should be interpreted in the context of recently re-
ported phase III studies, evaluating the potential utility of a universal
BMA treatment approach for all post-menopausal women receiving AI.
Recent large randomized studies in adjuvant AI treated breast cancer
patients have demonstrated, respectively: an improvement in BMD with
risedronate, as well as both an improvement in BMD plus a reduction in
fragility fractures with denosumab [18]. (Gnant et al., n.d.) These
ﬁndings, while clearly demonstrating the clinical utility of BMAs, do
not obviate the importance of ﬁnding better strategies to identify pa-
tients at risk of fragility fractures. An approach of universally treating
all patients starting therapy with an AI with a BMA has not been
adopted. Indeed, the majority of women will not experience a fragility
fracture, and therefore a universal treatment approach would lead to
overtreatment with BMAs, which may be costly and associated with
toxicities. When considering extended treatment with BMAs, rare ad-
verse eﬀects such as atypical femur fractures and osteonecrosis of the
jaw, likely related to duration of use, should be taken in consideration
[19]. An eﬀective screening approach may serve to better identify pa-
tients who may beneﬁt from BMAs.
Our study is limited by the number of subjects and its retrospective
nature. Additionally, an optimal TBS threshold for determining risk has
not been ﬁrmly established. The TBS categories used in our study have
been recently proposed by an international working group of TBS users,
and correspond to the tertiles for fracture risk as deﬁned in a recent
meta-analysis by McCloskey et al. In this study the thresholds of 1.23
and 1.31 deﬁned high risk and intermediate risk respectively, as the risk
for major osteoporotic fracture were signiﬁcantly higher in the highest
and intermediate tertile compared with the lowest-risk tertile
(TBS> 1.31) [8,20]. (“MEDIMAPS-UK-WEB.pdf,” n.d).
Fig. 3. Detection rates of AIs -associated fracture
risk, by timing of follow up DXA. A: Detection rate in
patients evaluated≤18 months from initiation of AI;
B: Detection rate in patients evaluated> 18 months
from initiation of AI. Legend: DXA, dual-energy X-
ray absorbimetry; AI, aromatase inhibition; BMD,
bone mineral density; FRAX, fracture risk assessment
tool; TBS, trabecular bone score.
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5. Conclusion
In conclusion, our retrospective analysis demonstrates that TBS
combined with the standard-of-care risk assessment tools BMD +
FRAX® may identify additional patients at high risk of fragility fracture
both before and during treatment with AIs, who may beneﬁt of treat-
ment with BMAs.
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